DarioHealth Corp (DRIO) — Titan Protect Analysis

DRIO

DarioHealth Corp

Healthcare · ·

$7.50

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$56M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-11.18

Based on estimated future earnings — lower means cheaper

Rev Growth

-31.2%

Year-over-year revenue change

Profit Margin

-186.6%

How much profit the company keeps from each dollar of revenue

ROE

-59.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$18.00

+140% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 4 analysts covering this stock

About DarioHealth Corp

DarioHealth Corp. operates as a digital health company in the United States and internationally. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Connect, a solution used to create communities around specific health conditions to increase awareness and education; Dario Mind, a b

https://www.dariohealth.com

Country: United States Employees: 160 Industry: Health Information Services

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

-0.021

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0334

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.591

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-47.2%

Historical annualised return based on price data

Max Drawdown

-79.8%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.09

Moves slightly more than the broader market

52W High

$17.74

58% below the year high

52W Low

$5.94

26% above the year low

Avg Volume

12,653

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-8.50

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

46.74

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

64.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-163.7%

Profit from core operations before interest and tax

Free Cash Flow

$-11,204,875

Negative — the business is spending more than it generates

Revenue (TTM)

$22M

Total revenue over the last 12 months

Net Income

$-40,309,576

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$28.00

Target Median

$18.00

Target Low

$10.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go